REMINDER: Metallus Announces Second-Quarter 2025 Earnings Webcast Details
CANTON, Ohio, Aug. 8, 2025 /PRNewswire/ — Metallus (NYSE: MTUS), a leader in high-quality specialty metals, manufactured components, and supply chain solutions,... Read more.
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida’s Agency for Health Care Administration (AHCA)
Florida’s Agency for Health Care Administration (AHCA) approval is a critical regulatory step toward closing the Dura Medical acquisition Dura Medical, together... Read more.
MEDIA ALERT: Equinix to Speak at Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 8, 2025 /PRNewswire/ — Equinix, Inc. (Nasdaq: EQIX), the world’s digital infrastructure company®, today announced that its... Read more.
LG CHANNELS GROWS NEWS VIEWERSHIP THROUGH ENHANCED USER EXPERIENCE
Improved Access to News Content and Strengthened Broadcast Partnerships InspireDouble-Digit Growth ENGLEWOOD CLIFFS, N.J., Aug. 8, 2025 /PRNewswire/ — LG Electronics... Read more.
VerifyMe to Report First Quarter 2025 Financial Results on August 13, 2025
LAKE MARY, Fla., Aug. 8, 2025 /PRNewswire/ — VerifyMe, Inc. (NASDAQ: VRME) (“VerifyMe,” “we,” “our,” or the “Company”)... Read more.
Accel-KKR Closes $1.9 Billion Continuation Fund to Support Further Growth of isolved
Fund Includes Commitment of $350 Million in New Capital to Accelerate isolved’s Growth Through Organic Initiatives and Accretive Acquisitions MENLO PARK, Calif.,... Read more.
Jennmar Expands International Presence with Acquisition of Weber Mining & Tunnelling SAS
Transaction Extends and Complements Jennmar’s Mining and Tunneling Customer Solutions Weber’s R&D Track Record Brings High-Quality Portfolio of Resin... Read more.
TDS announces third quarter 2025 dividends
CHICAGO, Aug. 8, 2025 /PRNewswire/ — The board of directors of Telephone and Data Systems, Inc. (NYSE: TDS) has declared third quarter 2025 dividends on its... Read more.
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million – $163 million... Read more.
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today... Read more.